- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02460250
Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death (FIBROSCAME)
According to the French Biomedicine Agency annual report on retrieval activities and transplants, 1,164 liver transplants were performed in 2011 and 1,161 in 2012. If the amount of brain death donors and retrieved liver grafts appears relatively stable, it remains clearly insufficient compared to the increasing number of patients on the waiting list for liver transplantation (2,462 in 2011). The median time on the waiting list before liver transplantation which was established from the cohort of patients registered between 2007 and 2011 (excluding patients registered for emergency transplantation and for living related-donor transplantation) increased significantly from 4.4 months between 2007 and 2009 to 6.6 months between 2010 and 2011. In order to compensate for the lack of liver grafts, donors acceptance criteria were broadened. For example, alternative transplantation lists were created with liver grafts coming from so-called "marginal" donors. However, despite these efforts, livers were retrieved on only two out of three brain death donors, i.e. in 1,572 and 1,589 organ donors in 2011 and 2012, respectively. This is unfortunately not enough to meet the increasing needs in liver grafts and a growing number of patients wait each year for transplant. Strategic lines of improvement were defined in order to meet the "2012-2016 transplant perspective" which targets 5,700 transplants carried out in 2015 (+5% every year, all transplants included, with 5,023 transplants in 2012).
According to the last consensus conference on liver transplantation of the HAS (French High Authority of Health) the assessment of the degree of macrovacuolar and microvacuolar steatosis determines the possibility to retrieve the graft or not. Liver steatosis consists in an accumulation of fatty droplets in hepatocytes. Its prevalence is high, ranging from 16% to 31% in the general population, and increases up to 46% in heavy drinkers and to 50-80% in the obese population. Steatosis results mostly from alcohol consumption and from metabolic syndrome (obesity, type 2 diabetes, hypertriglyceridemia) called non-alcoholic fatty liver disease (NAFLD), and is more rarely secondary to viral hepatitis or exposure to certain medications. NAFLD involves up to 30% of the population in Western countries and its prevalence is increasing. NAFLD may lead to asymptomatic steatosis, but also to steatohepatitis or advanced fibrosis including cirrhosis and its complications Accordingly, the improvement of liver grafts selection based on objective quantitative criteria which takes into account the degree of liver steatosis appears crucial to increase the number of hepatic transplants.
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Amiens, Frankreich, 80054
- University Hospital
-
Angers, Frankreich, 49100
- University Hospital
-
Besançon, Frankreich, 25030
- University Hospital
-
Bordeaux, Frankreich, 33000
- University Hospital
-
Brest, Frankreich, 29200
- University Hospital
-
Caen, Frankreich, 14033
- University Hospital
-
Clermont Ferrand, Frankreich, 63100
- Estaing University Hospital
-
Creteil, Frankreich, 94010
- AP-HP Henri Mondor
-
Grenoble, Frankreich, 38043
- University Hospital
-
Lille, Frankreich, 59037
- University Hospital
-
Limoges, Frankreich, 87042
- University Hospital
-
Lyon, Frankreich, 69004
- Croix Rousse Hospital
-
Nice, Frankreich, 06000
- Nice University Hospital
-
Paris, Frankreich, 84270
- AP-HP Kremlin Bicêtre
-
Poitiers, Frankreich, 86021
- University Hospital
-
Reims, Frankreich, 51100
- Univesity Hospital
-
Rennes, Frankreich, 35033
- University Hospital
-
Tours, Frankreich, 37044
- University Hospital
-
Vandoeuvre-les-nancy, Frankreich, 54500
- University Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patients older than 18 years with recognized clinical brain death confirmed by clinical examination, who are considered for organ retrieval and clinically stable to achieve the retrieval procedure
Exclusion Criteria:
- Personal objection to organ retrieval and clinical research expressed during lifetime and registered in the Registre National des Refus (French registration of all refusals to organ donation)
- Family objection to liver retrieval after donor's death
- Ongoing pregnancy when brain death is declared
- For FT and ST measurements included in the panel FibroMaxTM, 4 exclusion criteria are defined specifically (Acute hepatitis or cytolysis with ALT higher than 622 IU/L, acute or chronic hemolysis, extrahepatic cholestasis, sepsis)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Diagnose
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Fibroscan
All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
Liver recipients will be followed up during one year.
Biological and medical data used by all transplant sites for the follow-up of transplant patient will be collected
|
All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Controlled Attenuation Parameter™ (CAP™) measurement
Zeitfenster: 1 Day
|
Evaluation of the diagnostic accuracy of the CAP™ measured with Fibroscan® to objectively reflect the degree of liver steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in donors with brain death (DBD).
|
1 Day
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Liver Stiffness (LS) measurement
Zeitfenster: 1 Day
|
Evaluation of the diagnostic accuracy of LS measured with Fibroscan® to objectively reflect the degree of fibrosis and steatosis, a parameter which can be used as an aid in selecting liver grafts before retrieval in DBD
|
1 Day
|
Controlled Attenuation Parameter™ (CAP™) measurement
Zeitfenster: 1 week
|
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week after transplantation
|
1 week
|
Liver Stiffness (LS) measurement
Zeitfenster: 1 week
|
Determination of the prognostic value of LS in terms of survival of liver grafts at one week after transplantation
|
1 week
|
Liver Stiffness (LS) measurement
Zeitfenster: 1 month
|
Determination of the prognostic value of LS in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Controlled Attenuation Parameter™ (CAP™) measurement
Zeitfenster: 1 month
|
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Liver Stiffness (LS) measurement
Zeitfenster: 1 year
|
Determination of the prognostic value of LS in terms of survival of liver grafts at one week, one month and one year after transplantation
|
1 year
|
Controlled Attenuation Parameter™ (CAP™) measurement
Zeitfenster: 1 year
|
Determination of the prognostic value of CAP™ in terms of survival of liver grafts at one week, one month and one year after transplantation
|
1 year
|
Fibrosis measurement
Zeitfenster: 1 Day
|
evaluate the diagnostic a accuracy of FibroTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS
|
1 Day
|
Steatosis measurement
Zeitfenster: 1 Day
|
evaluate the diagnostic a accuracy of SteatoTest in selecting liver grafts before retrieval in DBD by comparing with 1) histological data obtained with liver biopsy (degree of steatosis, degree of fibrosis) and with 2) CAPTM/LS
|
1 Day
|
Fibrosis measurement
Zeitfenster: 1 month
|
Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Steatosis measurement
Zeitfenster: 1 month
|
Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one month after transplantation
|
1 month
|
Fibrosis measurement
Zeitfenster: 1 year
|
Determination of the short-term prognostic values of FibroTest in terms of survival of liver grafts at one year after transplantation
|
1 year
|
Steatosis measurement
Zeitfenster: 1 year
|
Determination of the short-term prognostic values of SteatoTest in terms of survival of liver grafts at one year after transplantation
|
1 year
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Nicolas PICHON, MD, University Hospital, Limoges
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- I12033 FIBROSCAME
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Lebertransplantation
-
University Health Network, TorontoNoch keine RekrutierungSolide Organtransplantation | Leber-Transplantation | Nierentransplantation | Herz Transplantation
-
Washington University School of MedicineNational Marrow Donor Program; Predictive BioDiagnostics, LLCAbgeschlossenTransplantation hämatopoetischer Stammzellen | Stammzelltransplantation, hämatopoetisch | Transplantation, hämatopoetische StammzelleVereinigte Staaten
-
Assistance Publique - Hôpitaux de ParisRekrutierungTransplantation | Haploidentische TransplantationFrankreich
-
University of SydneyUniversity of ManitobaNoch keine RekrutierungAblehnung; Transplantation, Niere | Ablehnung; Transplantation, BauchspeicheldrüseAustralien, Kanada, Neuseeland
-
University Health Network, TorontoNoch keine RekrutierungTransplantation; Scheitern, Herz | Transplantation; Versagen, Leber | Transplantation;Versagen,Niere | Transplantation; Versagen, Bauchspeicheldrüse | Transplantation; Versagen, Lunge(n)Kanada
-
Icahn School of Medicine at Mount SinaiThe Hospital for Sick Children; Baylor College of Medicine; Children's Hospital... und andere MitarbeiterAktiv, nicht rekrutierendVerbesserung der Medikamentenadhärenz bei Jugendlichen, die eine Lebertransplantation hatten (iMALT)TransplantationVereinigte Staaten, Kanada
-
CareDxBeendetTransplantationVereinigte Staaten
-
University of California, San FranciscoBristol-Myers SquibbZurückgezogenTransplantation
-
Southern Medical University, ChinaThird Affiliated Hospital, Sun Yat-Sen University; 181 Central Hospital of the...Abgeschlossen
Klinische Studien zur Fibroscan
-
EchosensRekrutierung
-
Assiut UniversityNoch keine Rekrutierung
-
Assistance Publique - Hôpitaux de ParisBeendetHepatitis, viral, menschlichFrankreich
-
Helen Kovari-KramerSwiss HIV Cohort StudyUnbekanntHIV-Infektion und chronische Alanin-Aminotransferase-ErhöhungSchweiz
-
Centre Hospitalier Universitaire DijonAbgeschlossenHepatische Steatose | Versagen der HypophyseFrankreich
-
University of AarhusAktiv, nicht rekrutierendLeberentzündung | Primäre biliäre ZirrhoseDänemark
-
HaEmek Medical Center, IsraelBeendetPatienten mit FettlebererkrankungIsrael
-
VA Connecticut Healthcare SystemAbgeschlossenChronische LebererkrankungVereinigte Staaten
-
King's College Hospital NHS TrustUnbekanntLeberkrankheiten | Schwangerschaftskrankheit
-
Chang Gung Memorial HospitalUnbekannt